USFDA Draft Rules Could Boost Indian Biotech in Biosimilar Market

Imagine medicines made from living things, like vaccines, which are very expensive.

Companies called the USFDA want to make it easier and cheaper to create 'biosimilars.'

These are like very similar, less expensive versions of those costly medicines.

The USFDA is proposing to lower the number of tests companies need to do, especially the really long and expensive ones where they test the medicine on people.

This is expected to help Indian companies, which are good at making cheaper medicines, to sell more of these biosimilars in the US.

It could mean more people can get treatments for diseases like cancer and diabetes without spending so much money.

It also makes it simpler for pharmacists and patients to choose these more affordable options.